Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

1478800

USP

Orlistat

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

(−)-Tetrahydrolipstatin, N-Formyl-L-leucin-(1S)-1-{[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]-methyl}-dodecylester, Ro-18-0647

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C29H53NO5
CAS-Nummer:
96829-58-2
Molekulargewicht:
495.73
MDL-Nummer:
MFCD05662360
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329750618
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

orlistat

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

InChIKey

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Angaben zum Gen

human ... LIPF(8513) , PNLIP(5406)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem./physiol. Wirkung

Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Solution is not completely clear, small particles may remain floating.
Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1478833

Orlistat-verwandte Verbindung C, United States Pharmacopeia (USP) Reference Standard

1478811

Orlistat-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1478844

Orlistat-verwandte Verbindung D, United States Pharmacopeia (USP) Reference Standard

1478855

Orlistat-verwandte Verbindung E, United States Pharmacopeia (USP) Reference Standard

1478822

Orlistat-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1680685

Tributylphosphinoxid, United States Pharmacopeia (USP) Reference Standard

PHR2544

Orlistat-verwandte Verbindung C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2543

Orlistat-verwandte Verbindung B, Pharmaceutical Secondary Standard; Certified Reference Material

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Juliet M Mancino
Current diabetes reports, 6(5), 389-394 (2006-11-02)
Orlistat, a pancreatic lipase inhibitor, was approved by the US Food and Drug Administration (FDA) in the spring of 1999 as an adjunct to lifestyle intervention for weight loss. This paper seeks to examine current issues regarding orlistat use in
Robert H Nelson et al.
Expert opinion on pharmacotherapy, 6(14), 2483-2491 (2005-11-02)
Orlistat (tetrahydrolipstatin) is an inhibitor of gastrointestinal lipases, especially pancreatic lipase. It is used as an adjunct to diet and exercise in order to achieve weight loss in obese individuals (body mass index > 30 kg/m2) or in overweight individuals
D N Kiortsis et al.
Diabetes & metabolism, 31(1), 15-22 (2005-04-02)
Orlistat is an antiobesity drug with a well documented efficacy in weight reduction and weight maintenance. Weight reduction with orlistat has been associated with a favourable effect on obesity-related cardiovascular risk factors. Orlistat treatment is associated with a reduction in
György Paragh et al.
Orvosi hetilap, 146(11), 493-498 (2005-04-09)
The overweight and obesity represent severe problems for the health management system of developed countries. In the evolution of obesity, beside genetic background, the environmental factors also play important roles. In the daily routine, the majority of obese patients need
Sheridan Henness et al.
Drugs, 66(12), 1625-1656 (2006-09-08)
Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.